ArticleJournal of thoracic disease2026
Safety and efficacy of low-dose versus high-dose alteplase for pulmonary embolism: a retrospective study from MIMIC-IV.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of low-dose thrombolysis in acute intermediate-high risk pulmonary thromboembolism complicated by PaOFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimal dosing of alteplase for systemic thrombolysis in intermediate-risk pulmonary embolism (PE) remains controversial due to hemorrhagic risk. This retrospective cohort study analyzed data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database to evaluate dose-dependent efficacy and safety of alteplase in PE patients. Methods: Patients with PE treated with systemic alteplase thrombolysis were stratified into two groups based on a clinically established dose threshold of 50 mg. The primary outcomes included 7-day mortality and changes in hemodynamic and respiratory parameters before and after alteplase administration. Secondary outcomes included the relationship between dose stratification and mortality at the intensive care unit (ICU), hospital, 28-, 60-, and 365-day, using Kaplan-Meier survival curves and Cox proportional hazards regression. Propensity score matching (PSM) was employed to minimize bias. Results: After PSM, 122 patients were included, with 76 in the low-dose group and 46 in the high-dose group. Both groups showed improvements in heart rate (HR). In the high-dose group, partial thromboplastin time (PTT) and blood urea nitrogen (BUN) were significantly higher than in the low-dose group. The low-dose group had lower 7-day and ICU mortality rates than the high-dose group. Cox regression analysis showed that dose stratification was an independent risk factor for 7-day mortality [hazard ratio (HR): 0.289, 95% confidence interval (CI): 0.072-1.023, P=0.045]. Conclusions: This study suggests that low-dose alteplase (≤50 mg) is associated with a better balance between thrombolytic efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.